Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [6][16]. Core Views - The company achieved a revenue of 1.295 billion yuan in 2024, representing a year-on-year growth of 20.79%. However, the net profit attributable to shareholders decreased by 16.62% to 261 million yuan. In Q1 2025, revenue reached 316 million yuan, up 27.08%, with net profit increasing by 75.85% to 76 million yuan [1][3]. - The company is focusing on strategic investments in four key areas: industrial measurement and control, smart logistics, energy and environmental measurement, and robotic sensors. In Q1 2025, it completed a strategic investment in Kepler Robotics [7][8]. Financial Summary - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are projected at 1.530 billion yuan, 1.830 billion yuan, and 2.231 billion yuan, respectively, with growth rates of 18.2%, 19.6%, and 21.9% [3][8]. - **Net Profit Forecast**: The net profit attributable to shareholders is forecasted to be 364 million yuan in 2025, 420 million yuan in 2026, and 505 million yuan in 2027, with growth rates of 40.0%, 15.2%, and 20.1% respectively [3][8]. - **Earnings Per Share (EPS)**: EPS is projected to be 1.30 yuan in 2025, 1.49 yuan in 2026, and 1.79 yuan in 2027 [3][8]. - **Valuation Metrics**: The company is assigned a target price of 78.0 yuan based on a 60x PE ratio for 2025, with the current price at 65.87 yuan [3][8]. Market Position and Strategy - The company is developing a "sensor forest" strategy, focusing on multi-physical quantity sensors, with significant growth in the mechanical sensor and instrument segment, which generated 631 million yuan in revenue with a gross margin of 41.81% [7][8]. - The company has sent samples of its six-dimensional force sensors to over 50 clients, with some entering the bulk order phase, indicating strong market demand [7][8].

Investment Rating - The report maintains a "Strong Buy" rating for Guizhou Moutai with a target price of 2600 CNY [1][4]. Core Views - The management conveyed confidence in the company's quality, culture, and foundational strength during the 2024 annual shareholders' meeting, emphasizing the resilience of Moutai's brand and its ability to navigate through market cycles [2][8]. - The company is focusing on strategic initiatives to adapt to current challenges, including enhancing customer engagement, service upgrades, and international expansion [8][9]. - The report highlights Moutai's strong performance in the first quarter, indicating its leading position in the liquor industry and the stabilization of product prices, which further enhances investment certainty [8][9]. Financial Summary - Total revenue projections for Guizhou Moutai are as follows: - 2024: 174,144 million CNY - 2025: 190,775 million CNY (growth of 9.6%) - 2026: 207,395 million CNY (growth of 8.7%) - 2027: 223,719 million CNY (growth of 7.9%) [4][10]. - Net profit forecasts are: - 2024: 86,228 million CNY - 2025: 94,679 million CNY (growth of 9.8%) - 2026: 103,603 million CNY (growth of 9.4%) - 2027: 112,623 million CNY (growth of 8.7%) [4][10]. - Earnings per share (EPS) estimates are: - 2024: 68.64 CNY - 2025: 75.37 CNY - 2026: 82.47 CNY - 2027: 89.65 CNY [4][10]. Market Position - Guizhou Moutai's market capitalization is approximately 19,395.69 billion CNY, with a total share capital of 125,619.78 million shares [5][10]. - The company maintains a low debt-to-equity ratio of 0.2%, indicating strong financial health and stability [10].

Investment Rating - The report maintains a "Strong Buy" rating for Guizhou Moutai with a target price of 2600 CNY [1][4]. Core Views - The management conveyed confidence in the company's quality, culture, and foundational strength during the 2024 annual shareholders' meeting, emphasizing the resilience of Moutai's brand and its ability to adapt through market cycles [2][4]. - The company is focusing on strategic initiatives to navigate current challenges, including enhancing customer engagement, service upgrades, and international expansion [4][4]. - The report highlights Moutai's strong performance in the first quarter, indicating that the company is well-positioned to maintain its leadership in the liquor industry [4][4]. Financial Summary - Projected total revenue for 2024 is 174.144 billion CNY, with a year-on-year growth rate of 15.7%. This is expected to grow to 190.775 billion CNY in 2025, representing a 9.6% increase [4][4]. - The net profit attributable to shareholders is projected to be 86.228 billion CNY in 2024, with a growth rate of 15.4%, increasing to 94.679 billion CNY in 2025 [4][4]. - Earnings per share (EPS) are forecasted to be 68.64 CNY for 2024, rising to 75.37 CNY in 2025 [4][4]. Market Position - Guizhou Moutai's market capitalization is approximately 1939.569 billion CNY, with a low debt ratio of 19.04%, indicating strong financial health [4][4]. - The company has maintained a high gross margin of around 91.9% to 92.2% over the forecast period, showcasing its pricing power and operational efficiency [4][4].

证 券 研 究 报 告 电动车行业周报（20250512-20250516） 国轩科技发布六大新品，冠鸿智能创新干法电极设 推荐（维持） 备技术 国轩科技发布六大新品，冠鸿智能创新干法电极设备技术。国轩科技在 2025 年 5 月 17 日发布六大新品。分别为为 G 垣准固态电池、启晨二代电芯、G 行超级重卡 标准箱、乾元智储 20MWh 储能电池系统、Axtrem 数智化解决方案、金石全固态电 池。在第十七届深圳国际电池技术交流会上，冠鸿智能的干法电极设备同时支持三 元锂、碳酸铁锂、钠电及硫化物/聚合物固态电解质膜制备，一机打通多技术路线。 在性能上，该设备的纤维化丝径小于 50nm(达行业顶尖水平)；极片压实密度大于 3.5g/cm，首效大于 91%；膜厚 15-150μm 自由调控，强度 1-4N/ ㎡ 媲美湿法工艺。 本周行情回顾：本周电新板块上涨 1.43%，全行业排名 8 名，跑赢沪深 300 指数。 根据中信行业指数，本周电力设备及新能源板块上涨 1.43%，在全行业 30 个行业 板块中排名第 8 位；同期沪深 300 指数上涨 1.12%，电新板块跑赢沪深 300 指数 0.32pcts。 ...

中美谈判超预期，关注后续进程 ——可转债周报 20250519 2025 年 5 月 12 日，中美双方发表《中美日内瓦经贸会谈联合声明》，宣布在 未来 90 天内暂停征收部分加征关税，会谈结果超出市场普遍预期。从结果上 来看： 债券研究 证 券 研 究 报 告 【债券周报】 中美关税冲突缓和，权益市场小幅回暖。本轮会谈大幅降低双边关税，中美贸 易冲突的扰动有所缓和，且在结果超预期的助力下权益市场情绪显著提振，恒 生指数 5 月 12 日涨幅 2.98%，万得全 A 上涨 1.29%，中证转债指数微涨 0.60%。 分板块来看，由于关税调降导致中国制造商成本快速下降以及风偏修复，前期 处于压力的制造及科技板块率先抬升，对应转债均价抬升但弹性较权益偏弱， 估值被动压缩，而医药医疗及周期板块则显得相对平淡。 谨慎情绪仍在，或需继续关注谈判进程。5 月 13 日市场表现出一定回调，这 一角度来看短期谨慎情绪或仍未完全消散，本轮贸易冲突的缓和不难使人联想 到 2019 年。从参考时点来看，存在两种不同假设，类比年初的"协议停战" 还是年底的第一阶段经贸协议，或代表两类完全相反的风险偏好，在特朗普政 策反复的假设下后续 ...

证 券 研 究 报 告 【债券日报】 转债市场日度跟踪 20250519 市场概况：今日转债缩量上涨，估值环比抬升 指数表现：中证转债指数环比上涨 0.14%、上证综指环比上涨 0.00%、深证成 指环比下降 0.08%、创业板指环比下降 0.33%、上证 50 指数环比下降 0.43%、 中证 1000 指数环比上涨 0.45%。 市场风格：小盘价值相对占优。大盘成长环比下降 0.62%、大盘价值环比下降 0.13%、中盘成长环比下降 0.33%、中盘价值环比上涨 0.02%、小盘成长环比 下降 0.07%、小盘价值环比上涨 0.48%。 资金表现：转债市场成交情绪减弱。可转债市场成交额为 559.77 亿元，环比 减少 15.37%；万得全 A 总成交额为 11188.82 亿元，环比减少 0.47%；沪深两 市主力净流出 124.08 亿元，十年国债收益率环比上升 1.00bp 至 1.69%。 转债价格：转债中枢提升，高价券占比下降。转债整体收盘价加权平均值为 119.08 元，环比昨日上升 0.13%。其中偏股型转债的收盘价为 158.40 元，环比 下降 0.19%；偏债型转债的收盘价为 109. ...

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [17]. Core Views - The company is experiencing a steady advancement in smart healthcare, with its Hi-HIS system moving towards a new phase of nationwide promotion [7]. - In 2024, the company reported a revenue of 1.423 billion yuan, a year-on-year decline of 11.96%, and a net loss attributable to shareholders of 174 million yuan, compared to a profit of 37 million yuan in the previous year [1][3]. - The first quarter of 2025 saw a revenue of 290 million yuan, down 22.67% year-on-year, with a net loss of 16 million yuan, marking the first quarterly loss [1][3]. Financial Performance Summary - The total revenue for 2024 was 1.423 billion yuan, with a projected increase to 1.596 billion yuan in 2025, reflecting a growth rate of 12.2% [3]. - The net profit attributable to shareholders is expected to recover from a loss of 174 million yuan in 2024 to a profit of 77 million yuan in 2025, indicating a significant turnaround [3]. - The gross margin for 2024 was 45.18%, which is a decrease of 1.80 percentage points from the previous year, while the gross margin for Q1 2025 improved to 55.12%, an increase of 3.51 percentage points [7]. Market Position and Growth Potential - The company is positioned among the top tier of domestic healthcare information software providers and is expected to benefit from the ongoing push for healthcare informationization [7]. - In 2024, the company secured 31 new software orders in the smart healthcare and public health sectors, totaling 580 million yuan, with a year-on-year increase of 41% in order quantity [7]. - The company aims to achieve revenues of 1.596 billion yuan, 1.795 billion yuan, and 2.010 billion yuan for the years 2025, 2026, and 2027, respectively [7].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 278 yuan [2][7]. Core Views - The company is experiencing a structural upgrade towards high-end products and is making significant progress in international markets. The total revenue for 2024 is projected to be 36.726 billion yuan, reflecting a year-on-year growth of 5.14%. The net profit attributable to the parent company is expected to be 11.668 billion yuan, with a slight increase of 0.74% [2][3]. Financial Performance Summary - **2024 Financials**: Total revenue is 36.726 billion yuan, with a year-on-year growth of 5.1%. The net profit attributable to the parent company is 11.668 billion yuan, showing a growth of 0.7% [3]. - **2025 Projections**: Expected revenue growth of 8.4% to 39.827 billion yuan and net profit growth of 7.5% to 12.545 billion yuan [3]. - **2026 and 2027 Outlook**: Revenue is projected to reach 45.883 billion yuan in 2026 and 52.779 billion yuan in 2027, with respective growth rates of 15.2% and 15.0%. Net profit is expected to be 14.832 billion yuan in 2026 and 17.233 billion yuan in 2027, with growth rates of 18.2% and 16.2% [3][8]. Market Dynamics - The international market is showing robust growth, with a 21.28% increase in 2024. The Asia-Pacific region, driven by countries like Australia, Thailand, and India, has seen nearly 40% growth. The European market has rebounded with over 30% growth [7]. - Domestic market performance has been under pressure, with a decline of 5.10% in 2024, primarily due to sluggish procurement processes. However, a rebound is anticipated in Q3 2025 as fiscal conditions improve [7]. Business Segment Performance - **IVD Business**: This segment has shown a growth of 10.82% in 2024, with international IVD growth exceeding 30%. IVD has become the largest business segment, accounting for 37.48% of total revenue [7]. - **Medical Imaging**: This segment grew by 6.60%, with international growth over 15%. The domestic high-end ultrasound market has also seen significant performance [7]. - **Life Information and Support**: This segment faced a decline of 11.11%, but international growth remains strong [7]. Valuation Metrics - The report estimates a DCF-based valuation of 337.1 billion yuan for the company, translating to a target price of approximately 278 yuan, which corresponds to a PE ratio of 27 times for 2025 [7].

证 券 研 究 报 告 自媒体热度持续上升，散户资金净流入小幅增加 ——投资者温度计第25期 2025年5月19日 证券分析师：姚佩 执业编号：S0360522120004 邮箱：yaopei@hcyjs.com 联系人：朱冬墨 邮箱：zhudongmo@hcyjs.com 本报告由华创证券有限责任公司编制 核心结论 证 券 研 究 报 告 证监会审核华创证券投资咨询业务资格批文号：证监许可（2009）1210 号 2 • 上周市场整体上行，受5/12中美关税谈判"超预期"落地，自媒体热度持续上升。 • 公募抱团趋势增强，风格偏向价值，行业偏向消费、周期；24/9/18至今公募重仓股四成领涨，行业集中于电子、 汽车、医药等。 • 最近一周以小单衡量的沪深两市A股散户资金净流入821.9亿元，较前值增加203.9亿元，处过去五年36.0%分 位，净流入规模小幅增加；融资资金净流入24.1亿元，较上周减少143.4亿元。 1.1、自媒体：热度持续上升 证 券 研 究 报 告 • 上周市场整体上行， 受5/12中美关税谈 判"超预期"落地， 自媒体热度持续上升。 从趋势上来看，快手、 抖音热度保持前列， 微博、百度 ...

证 券 研 究 报 告 电动车行业周报（20250512-20250516） 国轩科技发布六大新品，冠鸿智能创新干法电极设 推荐（维持） 备技术 国轩科技发布六大新品，冠鸿智能创新干法电极设备技术。国轩科技在 2025 年 5 月 17 日发布六大新品。分别为为 G 垣准固态电池、启晨二代电芯、G 行超级重卡 标准箱、乾元智储 20MWh 储能电池系统、Axtrem 数智化解决方案、金石全固态电 池。在第十七届深圳国际电池技术交流会上，冠鸿智能的干法电极设备同时支持三 元锂、碳酸铁锂、钠电及硫化物/聚合物固态电解质膜制备，一机打通多技术路线。 在性能上，该设备的纤维化丝径小于 50nm(达行业顶尖水平)；极片压实密度大于 3.5g/cm，首效大于 91%；膜厚 15-150μm 自由调控，强度 1-4N/ ㎡ 媲美湿法工艺。 本周行情回顾：本周电新板块上涨 1.43%，全行业排名 8 名，跑赢沪深 300 指数。 根据中信行业指数，本周电力设备及新能源板块上涨 1.43%，在全行业 30 个行业 板块中排名第 8 位；同期沪深 300 指数上涨 1.12%，电新板块跑赢沪深 300 指数 0.32pcts。 ...